Phase II study of divided-dose vinblastine in advanced breast cancer patients Academic Article uri icon


MeSH Major

  • Breast Neoplasms
  • Vinblastine


  • The pharmacokinetics of a 5-day, continuous infusion of vinblastine have been reproduced by an i.v. divided bolus at 0 and 48 h [10]; this schedule can be easily applied to outpatients. We treated 26 evaluable patients with refractory, advanced breast cancer with 3.5-4 mg/m2 vinblastine given i.v. by a divided bolus at 0 and 48 h of 21-day cycles. Neurotoxicity and myelosuppression were the main side effects: severe constipation and peripheral neurotoxicity developed in 14% and 3% of the patients, respectively; severe leukopenia and thrombocytopenia occurred in 24% and 10% of the patients, respectively. One partial response, 14 no changes, and 11 progressions were obtained. Our results do not support the use of vinblastine in divided doses in treating this disease.

publication date

  • February 1988



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1007/BF00262742

PubMed ID

  • 3342466

Additional Document Info

start page

  • 65

end page

  • 7


  • 21


  • 1